{"name":"Takeda Pharmaceutical Company Limited","slug":"takeda","ticker":"TAK","exchange":"NYSE","domain":"takeda.com","description":"The Takeda Pharmaceutical Company Limited  is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.","hq":"Tokyo, Japan","founded":1781,"employees":"47455","ceo":"Christophe Weber","sector":"Big Pharma","stockPrice":18.62,"stockChange":0.33,"stockChangePercent":1.8,"marketCap":"$58.8B","metrics":{"revenue":4464578134016,"revenueGrowth":4.2,"grossMargin":65.5,"rdSpend":0,"netIncome":112925999104,"cash":654937030656,"dividendYield":3.63,"peRatio":84.7,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Entyvio","genericName":"vedolizumab","slug":"vedolizumab","revenue":7300000000,"yoyGrowth":0,"percentOfTotal":58.4},{"name":"Vyvanse","genericName":"LISDEXAMFETAMINE","slug":"lisdexamfetamine","revenue":3200000000,"yoyGrowth":0,"percentOfTotal":25.6},{"name":"Trintellix","genericName":"vortioxetine","slug":"vortioxetine","revenue":800000000,"yoyGrowth":0,"percentOfTotal":6.4},{"name":"Ninlaro","genericName":"IXAZOMIB","slug":"ixazomib","revenue":600000000,"yoyGrowth":0,"percentOfTotal":4.8},{"name":"Dexilant","genericName":"DEXLANSOPRAZOLE","slug":"dexlansoprazole","revenue":300000000,"yoyGrowth":0,"percentOfTotal":2.4},{"name":"Livtencity","genericName":"MARIBAVIR","slug":"maribavir","revenue":300000000,"yoyGrowth":0,"percentOfTotal":2.4}],"timeline":[{"date":"1945-01-01","label":"Furacin first approved","drug":"Furacin","drugSlug":"nitrofurazone","type":"approval","sentiment":"positive"},{"date":"1951-01-01","label":"Banthine first approved","drug":"Banthine","drugSlug":"methanthelinium","type":"approval","sentiment":"positive"},{"date":"1958-01-01","label":"Furazol first approved","drug":"Furazol","drugSlug":"furazolidone","type":"approval","sentiment":"positive"},{"date":"1985-01-01","label":"Versed first approved","drug":"Versed","drugSlug":"midazolam-hydrochloride","type":"approval","sentiment":"positive"},{"date":"1997-01-01","label":"Agrylin first approved","drug":"Agrylin","drugSlug":"anagrelide","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Rozerem first approved","drug":"Rozerem","drugSlug":"ramelteon","type":"approval","sentiment":"positive"},{"date":"2006-01-01","label":"Omnaris first approved","drug":"Omnaris","drugSlug":"alvesco","type":"approval","sentiment":"positive"},{"date":"2006-01-01","label":"Elaprase first approved","drug":"Elaprase","drugSlug":"idursulfase","type":"approval","sentiment":"positive"},{"date":"2007-01-01","label":"Vyvanse first approved","drug":"Vyvanse","drugSlug":"lisdexamfetamine","type":"approval","sentiment":"positive"},{"date":"2009-01-01","label":"Dexilant first approved","drug":"Dexilant","drugSlug":"dexlansoprazole","type":"approval","sentiment":"positive"},{"date":"2009-01-01","label":"Uloric first approved","drug":"Uloric","drugSlug":"febuxostat","type":"approval","sentiment":"positive"},{"date":"2011-01-01","label":"Firazyr first approved","drug":"Firazyr","drugSlug":"icatibant","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Gattex Kit first approved","drug":"Gattex Kit","drugSlug":"teduglutide","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Trintellix first approved","drug":"Trintellix","drugSlug":"vortioxetine","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Nesina first approved","drug":"Nesina","drugSlug":"alogliptin","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Ninlaro first approved","drug":"Ninlaro","drugSlug":"ixazomib","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Alunbrig first approved","drug":"Alunbrig","drugSlug":"brigatinib","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Livtencity first approved","drug":"Livtencity","drugSlug":"maribavir","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Exkivity first approved","drug":"Exkivity","drugSlug":"mobocertinib","type":"approval","sentiment":"positive"},{"date":"2026-05-22","label":"Entyvio Phase 3 readout (Crohn's Disease (CD))","drug":"Entyvio","drugSlug":"vedolizumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-08-02","label":"Dexilant patent expiry (Formulation)","drug":"Dexilant","drugSlug":"dexlansoprazole","type":"patent_expiry","sentiment":"negative"},{"date":"2026-09-27","label":"Dexilant patent expiry (Formulation)","drug":"Dexilant","drugSlug":"dexlansoprazole","type":"patent_expiry","sentiment":"negative"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-31","label":"Exkivity PHASE1,PHASE2 readout","drug":"Exkivity","drugSlug":"mobocertinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-02-02","label":"Dexilant patent expiry (Compound)","drug":"Dexilant","drugSlug":"dexlansoprazole","type":"patent_expiry","sentiment":"negative"},{"date":"2027-03-27","label":"Dexilant patent expiry (Compound)","drug":"Dexilant","drugSlug":"dexlansoprazole","type":"patent_expiry","sentiment":"negative"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-01-18","label":"Versed patent expiry (Formulation)","drug":"Versed","drugSlug":"midazolam-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2028-01-18","label":"Versed patent expiry (Formulation)","drug":"Versed","drugSlug":"midazolam-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2028-01-18","label":"Versed patent expiry (Formulation)","drug":"Versed","drugSlug":"midazolam-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2028-01-18","label":"Versed patent expiry (Formulation)","drug":"Versed","drugSlug":"midazolam-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2028-08-01","label":"Entyvio Phase 3 readout (Crohn's Disease)","drug":"Entyvio","drugSlug":"vedolizumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-11-30","label":"Entyvio Phase 3 readout (Ulcerative Colitis)","drug":"Entyvio","drugSlug":"vedolizumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-03-17","label":"Dexilant patent expiry (Method of Use)","drug":"Dexilant","drugSlug":"dexlansoprazole","type":"patent_expiry","sentiment":"negative"},{"date":"2030-09-17","label":"Dexilant patent expiry (Compound)","drug":"Dexilant","drugSlug":"dexlansoprazole","type":"patent_expiry","sentiment":"negative"},{"date":"2031-08-15","label":"Entyvio Phase 3 readout (Ulcerative Colitis, Crohn's Disease)","drug":"Entyvio","drugSlug":"vedolizumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2032-03-05","label":"Dexilant patent expiry (Method of Use)","drug":"Dexilant","drugSlug":"dexlansoprazole","type":"patent_expiry","sentiment":"negative"},{"date":"2038-06-20","label":"Versed patent expiry (Formulation)","drug":"Versed","drugSlug":"midazolam-hydrochloride","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Oxaliplatin patent cliff ($1.4B at risk)","drug":"Oxaliplatin","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Vedolizumab patent cliff ($2.5B at risk)","drug":"Vedolizumab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":7300000000,"percentOfTotal":58.4,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"Entyvio","genericName":"vedolizumab","slug":"vedolizumab","indication":"Chronic antibioticrefractory ileal pouchitis","status":"marketed","revenue":7300000000},{"name":"IGSC 20% infusion","genericName":"IGSC 20% infusion","slug":"igsc-20-infusion","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"ActHIB+ DPT-TAKEDA","genericName":"ActHIB+ DPT-TAKEDA","slug":"acthib-dpt-takeda","indication":"Active immunization against Haemophilus influenzae type b, diphtheria, pertussis, and tetanus in infants and children","status":"phase_3"},{"name":"Anti-TNF Therapy","genericName":"Anti-TNF Therapy","slug":"anti-tnf-therapy","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Celecoxib and aspirin","genericName":"Celecoxib and aspirin","slug":"celecoxib-and-aspirin","indication":"Cardiovascular event prevention in patients with chronic pain or arthritis requiring NSAID therapy","status":"phase_3"},{"name":"HyQvia","genericName":"HyQvia","slug":"hyqvia","indication":"Primary Immunodeficiency (PI)","status":"marketed"},{"name":"Placebo to match deucravacitinib","genericName":"Placebo to match deucravacitinib","slug":"placebo-to-match-deucravacitinib","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Tinoridine HCl","genericName":"Tinoridine HCl","slug":"tinoridine-hcl","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Vedolizumab IV","genericName":"Vedolizumab IV","slug":"vedolizumab-iv","indication":"Moderate to severe ulcerative colitis","status":"marketed"},{"name":"Vedolizumab SC","genericName":"Vedolizumab SC","slug":"vedolizumab-sc","indication":"Ulcerative colitis (induction and maintenance of remission)","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":4000000000,"percentOfTotal":32,"drugCount":7,"colorKey":"immunology","drugs":[{"name":"Vyvanse","genericName":"LISDEXAMFETAMINE","slug":"lisdexamfetamine","indication":"Attention Deficit Hyperactivity Disorder (ADHD)","status":"marketed","revenue":3200000000},{"name":"Trintellix","genericName":"vortioxetine","slug":"vortioxetine","indication":"Major Depressive Disorder (MDD)","status":"marketed","revenue":800000000},{"name":"Versed","genericName":"Midazolam Hydrochloride","slug":"midazolam-hydrochloride","indication":"Anxiety","status":"marketed"},{"name":"Firazyr","genericName":"ICATIBANT","slug":"icatibant","indication":"Hereditary angioneurotic edema","status":"marketed"},{"name":"AO-128","genericName":"AO-128","slug":"ao-128","indication":"Diabetic peripheral neuropathy","status":"marketed"},{"name":"TVP-1012","genericName":"TVP-1012","slug":"tvp-1012","indication":"Multiple sclerosis","status":"phase_3"},{"name":"Vortioxetine tablets","genericName":"Vortioxetine tablets","slug":"vortioxetine-tablets","indication":"Major depressive disorder","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":600000000,"percentOfTotal":4.8,"drugCount":14,"colorKey":"cardiovascular","drugs":[{"name":"Ninlaro","genericName":"IXAZOMIB","slug":"ixazomib","indication":"Multiple myeloma","status":"marketed","revenue":600000000},{"name":"Alunbrig","genericName":"brigatinib","slug":"brigatinib","indication":"Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","status":"marketed"},{"name":"Exkivity","genericName":"MOBOCERTINIB","slug":"mobocertinib","indication":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","status":"marketed"},{"name":"Mepact","genericName":"MIFAMURTIDE","slug":"mifamurtide","indication":"Osteosarcoma of bone","status":"marketed"},{"name":"TAK-667","genericName":"TAK-667","slug":"tak-667","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"},{"name":"TAK-771","genericName":"TAK-771","slug":"tak-771","indication":"Hepatocellular carcinoma (HCC), FGFR4-driven","status":"phase_3"},{"name":"Any FDA Approved ALK Inhibitors","genericName":"Any FDA Approved ALK Inhibitors","slug":"any-fda-approved-alk-inhibitors","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Chemotherapy Agents","genericName":"Chemotherapy Agents","slug":"chemotherapy-agents","indication":"Breast cancer","status":"phase_2"},{"name":"Leuprorelin Acetate Depot 3M","genericName":"Leuprorelin Acetate Depot 3M","slug":"leuprorelin-acetate-depot-3m","indication":"Advanced prostate cancer","status":"marketed"},{"name":"Leuprorelin acetate","genericName":"Leuprorelin acetate","slug":"leuprorelin-acetate","indication":"Advanced prostate cancer","status":"phase_3"},{"name":"SYR-472","genericName":"SYR-472","slug":"syr-472","indication":"Solid tumors with FGFR gene fusions or amplifications","status":"phase_3"},{"name":"TAK-019","genericName":"TAK-019","slug":"tak-019","indication":"Melanoma (in combination with checkpoint inhibitors)","status":"phase_3"},{"name":"TAP-144-SR(3M)","genericName":"TAP-144-SR(3M)","slug":"tap-144-sr-3m","indication":"Advanced prostate cancer","status":"phase_3"},{"name":"TAP-144-SR(6M)","genericName":"TAP-144-SR(6M)","slug":"tap-144-sr-6m","indication":"Advanced prostate cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":300000000,"percentOfTotal":2.4,"drugCount":47,"colorKey":"neuroscience","drugs":[{"name":"Dexilant","genericName":"DEXLANSOPRAZOLE","slug":"dexlansoprazole","indication":"Erosive esophagitis","status":"marketed","revenue":300000000},{"name":"Gattex Kit","genericName":"TEDUGLUTIDE","slug":"teduglutide","indication":"Short bowel syndrome","status":"marketed"},{"name":"RYMPHYSIA","genericName":"RYMPHYSIA","slug":"rymphysia","indication":"Other","status":"marketed"},{"name":"Ramelteon and zolpidem","genericName":"Ramelteon and zolpidem","slug":"ramelteon-and-zolpidem","indication":"Insomnia characterized by difficulty with sleep onset and/or sleep maintenance","status":"marketed"},{"name":"TAK-003","genericName":"TAK-003","slug":"tak-003","indication":"Prevention of dengue fever caused by dengue virus serotypes 1, 2, 3, and 4 in endemic populations","status":"phase_3"},{"name":"TAK-330","genericName":"TAK-330","slug":"tak-330","indication":"Other","status":"phase_3"},{"name":"YF-17D","genericName":"YF-17D","slug":"yf-17d","indication":"Prevention of yellow fever","status":"phase_3"},{"name":"AD-4833 15 mg","genericName":"AD-4833 15 mg","slug":"ad-4833-15-mg","indication":"Other","status":"marketed"},{"name":"Adcal-D3","genericName":"Adcal-D3","slug":"adcal-d3","indication":"Other","status":"marketed"},{"name":"Adynovate","genericName":"Adynovate","slug":"adynovate","indication":"Other","status":"marketed"},{"name":"Alogliptin and metformin","genericName":"Alogliptin and metformin","slug":"alogliptin-and-metformin","indication":"Other","status":"marketed"},{"name":"Alogliptin and pioglitazone","genericName":"Alogliptin and pioglitazone","slug":"alogliptin-and-pioglitazone","indication":"Other","status":"marketed"},{"name":"Banthine","genericName":"methanthelinium","slug":"methanthelinium","indication":"Gastric ulcer","status":"marketed"},{"name":"Calcichew D3","genericName":"Calcichew D3","slug":"calcichew-d3","indication":"Calcium and vitamin D3 deficiency","status":"marketed"},{"name":"Candesartan and Hydrochlorothiazide","genericName":"Candesartan and Hydrochlorothiazide","slug":"candesartan-and-hydrochlorothiazide","indication":"Other","status":"marketed"},{"name":"Coumarin/troxerutin","genericName":"Coumarin/troxerutin","slug":"coumarin-troxerutin","indication":"Chronic venous insufficiency","status":"marketed"},{"name":"Dexlansoprazole MR","genericName":"Dexlansoprazole MR","slug":"dexlansoprazole-mr","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"Dexlansoprazole MR QD","genericName":"Dexlansoprazole MR QD","slug":"dexlansoprazole-mr-qd","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"Esomeprazole Capsule","genericName":"Esomeprazole Capsule","slug":"esomeprazole-capsule","indication":"Other","status":"marketed"},{"name":"Fazirsiran Injection","genericName":"Fazirsiran Injection","slug":"fazirsiran-injection","indication":"Transfusion-dependent beta-thalassemia","status":"phase_3"},{"name":"Febuxostat IR","genericName":"Febuxostat IR","slug":"febuxostat-ir","indication":"Chronic management of hyperuricemia in patients with gout","status":"phase_3"},{"name":"Furazol","genericName":"FURAZOLIDONE","slug":"furazolidone","indication":"Other","status":"marketed"},{"name":"IGI, 10%","genericName":"IGI, 10%","slug":"igi-10","indication":"Other","status":"phase_3"},{"name":"Intramuscular injection of TAK-850","genericName":"Intramuscular injection of TAK-850","slug":"intramuscular-injection-of-tak-850","indication":"Other","status":"phase_1"},{"name":"Kalcipos-D","genericName":"Kalcipos-D","slug":"kalcipos-d","indication":"Hypocalcemia and vitamin D deficiency","status":"marketed"},{"name":"LIVTENCITY","genericName":"LIVTENCITY","slug":"livtencity","indication":"Other","status":"marketed"},{"name":"Lansoprazole microgranules suspension","genericName":"Lansoprazole microgranules suspension","slug":"lansoprazole-microgranules-suspension","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"Levothyroxine sodium new formulation","genericName":"Levothyroxine sodium new formulation","slug":"levothyroxine-sodium-new-formulation","indication":"Hypothyroidism","status":"phase_2"},{"name":"Magnesium Pantoprazole","genericName":"Magnesium Pantoprazole","slug":"magnesium-pantoprazole","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"NE-58095 DR","genericName":"NE-58095 DR","slug":"ne-58095-dr","indication":"Other","status":"phase_2"},{"name":"Norwalk VLP vaccine","genericName":"Norwalk VLP vaccine","slug":"norwalk-vlp-vaccine","indication":"Other","status":"phase_1"},{"name":"Olmesartan medoxomil and hydrochlorothiazide","genericName":"Olmesartan medoxomil and hydrochlorothiazide","slug":"olmesartan-medoxomil-and-hydrochlorothiazide","indication":"Other","status":"marketed"},{"name":"Omega-3 fatty acid ethyl esters","genericName":"Omega-3 fatty acid ethyl esters","slug":"omega-3-fatty-acid-ethyl-esters","indication":"Hypertriglyceridemia","status":"phase_2"},{"name":"Parathyroid Hormone (PTH)","genericName":"Parathyroid Hormone (PTH)","slug":"parathyroid-hormone-pth","indication":"Osteoporosis in postmenopausal women and men at high risk of fracture","status":"marketed"},{"name":"Pioglitazone and insulin","genericName":"Pioglitazone and insulin","slug":"pioglitazone-and-insulin","indication":"Other","status":"marketed"},{"name":"Pioglitazone and metformin and insulin","genericName":"Pioglitazone and metformin and insulin","slug":"pioglitazone-and-metformin-and-insulin","indication":"Other","status":"marketed"},{"name":"Placebo and zolpidem","genericName":"Placebo and zolpidem","slug":"placebo-and-zolpidem","indication":"Insomnia (sleep initiation and maintenance)","status":"marketed"},{"name":"Placebo to match zasocitinib","genericName":"Placebo to match zasocitinib","slug":"placebo-to-match-zasocitinib","indication":"Other","status":"phase_3"},{"name":"Rapid-acting insulin secretagogue","genericName":"Rapid-acting insulin secretagogue","slug":"rapid-acting-insulin-secretagogue","indication":"Other","status":"phase_3"},{"name":"Rozerem","genericName":"RAMELTEON","slug":"ramelteon","indication":"Initial insomnia","status":"marketed"},{"name":"Soticlestat 300 mg","genericName":"Soticlestat 300 mg","slug":"soticlestat-300-mg","indication":"Other","status":"phase_1"},{"name":"Surgicel® Original","genericName":"Surgicel® Original","slug":"surgicel-original","indication":"Hemostasis during surgical procedures (capillary, venous, and small arterial bleeding control)","status":"phase_3"},{"name":"TAK-085","genericName":"TAK-085","slug":"tak-085","indication":"Other","status":"marketed"},{"name":"Uloric","genericName":"FEBUXOSTAT","slug":"febuxostat","indication":"Gout Prevention","status":"marketed"},{"name":"VONVENDI","genericName":"VONVENDI","slug":"vonvendi","indication":"Von Willebrand disease (on-demand treatment and routine prophylaxis of bleeding episodes)","status":"marketed"},{"name":"Venticute","genericName":"Venticute","slug":"venticute","indication":"Other","status":"phase_3"},{"name":"mannitol and sucrose","genericName":"mannitol and sucrose","slug":"mannitol-and-sucrose","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":300000000,"percentOfTotal":2.4,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"Livtencity","genericName":"MARIBAVIR","slug":"maribavir","indication":"Post-transplant cytomegalovirus infection","status":"marketed","revenue":300000000},{"name":"Amoxicillin hydrate","genericName":"Amoxicillin hydrate","slug":"amoxicillin-hydrate","indication":"Uncomplicated urinary tract infections","status":"phase_2"},{"name":"Concomitant Antibiotic Therapy","genericName":"Concomitant Antibiotic Therapy","slug":"concomitant-antibiotic-therapy","indication":"Serious bacterial infections (specific indication dependent on Phase 3 trial design)","status":"phase_3"},{"name":"Furacin","genericName":"NITROFURAZONE","slug":"nitrofurazone","indication":"Enterobacter Cystitis","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":28,"colorKey":"rare","drugs":[{"name":"TAK-861","genericName":"TAK-861","slug":"tak-861","indication":"Treatment of type 2 diabetes","status":"phase_3"},{"name":"TAK-881","genericName":"TAK-881","slug":"tak-881","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TDV","genericName":"TDV","slug":"tdv","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Actos","genericName":"pioglitazone","slug":"pioglitazone","indication":"Diabetes mellitus type 2","status":"marketed"},{"name":"Alogliptin and glimepiride","genericName":"Alogliptin and glimepiride","slug":"alogliptin-and-glimepiride","indication":"Type 2 diabetes","status":"phase_2"},{"name":"Alogliptin and glyburide","genericName":"Alogliptin and glyburide","slug":"alogliptin-and-glyburide","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Alogliptin and insulin","genericName":"Alogliptin and insulin","slug":"alogliptin-and-insulin","indication":"Type 2 diabetes mellitus in patients inadequately controlled on insulin alone","status":"phase_3"},{"name":"Alogliptin and voglibose","genericName":"Alogliptin and voglibose","slug":"alogliptin-and-voglibose","indication":"Type 2 diabetes","status":"phase_2"},{"name":"Glibenclamide and Metformin","genericName":"Glibenclamide and Metformin","slug":"glibenclamide-and-metformin","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Glimepiride and Metformin","genericName":"Glimepiride and Metformin","slug":"glimepiride-and-metformin","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Lapaquistat acetate and atorvastatin","genericName":"Lapaquistat acetate and atorvastatin","slug":"lapaquistat-acetate-and-atorvastatin","indication":"Hypercholesterolemia / dyslipidemia (in combination therapy)","status":"phase_3"},{"name":"Lapaquistat acetate and ezetimibe","genericName":"Lapaquistat acetate and ezetimibe","slug":"lapaquistat-acetate-and-ezetimibe","indication":"Hypercholesterolemia / elevated LDL cholesterol","status":"phase_3"},{"name":"Lapaquistat acetate and rosuvastatin","genericName":"Lapaquistat acetate and rosuvastatin","slug":"lapaquistat-acetate-and-rosuvastatin","indication":"Hypercholesterolemia / elevated LDL cholesterol","status":"phase_3"},{"name":"Lapaquistat acetate and simvastatin","genericName":"Lapaquistat acetate and simvastatin","slug":"lapaquistat-acetate-and-simvastatin","indication":"Hypercholesterolemia / dyslipidemia (LDL cholesterol reduction)","status":"phase_3"},{"name":"Metformin and insulin","genericName":"Metformin and insulin","slug":"metformin-and-insulin","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Nesina","genericName":"ALOGLIPTIN","slug":"alogliptin","indication":"Diabetes mellitus type 2","status":"marketed"},{"name":"Pioglitazone and Glimepiride","genericName":"Pioglitazone and Glimepiride","slug":"pioglitazone-and-glimepiride","indication":"Glycemic Control in Type 2 Diabetes","status":"marketed"},{"name":"Pioglitazone and Metformin","genericName":"Pioglitazone and Metformin","slug":"pioglitazone-and-metformin","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Placebo to alogliptin","genericName":"Placebo to alogliptin","slug":"placebo-to-alogliptin","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"SYR-322-MET","genericName":"SYR-322-MET","slug":"syr-322-met","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TAK-279","genericName":"TAK-279","slug":"tak-279","indication":"Treatment of type 2 diabetes","status":"phase_3"},{"name":"TAK-385","genericName":"TAK-385","slug":"tak-385","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TAK-438","genericName":"TAK-438","slug":"tak-438","indication":"Treatment of type 2 diabetes","status":"phase_3"},{"name":"TAK-536","genericName":"TAK-536","slug":"tak-536","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TAK-536TCH","genericName":"TAK-536TCH","slug":"tak-536tch","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TAK-625","genericName":"TAK-625","slug":"tak-625","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TAK-755","genericName":"TAK-755","slug":"tak-755","indication":"Type 2 diabetes","status":"phase_3"},{"name":"TAK-816+ DPT-TAKEDA","genericName":"TAK-816+ DPT-TAKEDA","slug":"tak-816-dpt-takeda","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"metabolic","drugs":[{"name":"Agrylin","genericName":"ANAGRELIDE","slug":"anagrelide","indication":"Essential thrombocythemia","status":"marketed"},{"name":"Azilsartan Medoxomil and amlodipine","genericName":"Azilsartan Medoxomil and amlodipine","slug":"azilsartan-medoxomil-and-amlodipine","indication":"Hypertension","status":"phase_3"},{"name":"Azilsartan medoxomil - chlorthalidone","genericName":"Azilsartan medoxomil - chlorthalidone","slug":"azilsartan-medoxomil-chlorthalidone","indication":"Hypertension","status":"phase_3"},{"name":"Azilsartan medoxomil and chlorthalidone","genericName":"Azilsartan medoxomil and chlorthalidone","slug":"azilsartan-medoxomil-and-chlorthalidone","indication":"Hypertension","status":"phase_3"},{"name":"Azilsartan medoxomil and hydrochlorothiazide","genericName":"Azilsartan medoxomil and hydrochlorothiazide","slug":"azilsartan-medoxomil-and-hydrochlorothiazide","indication":"Hypertension (high blood pressure)","status":"phase_3"},{"name":"Azilsartan medoxomil and olmesartan","genericName":"Azilsartan medoxomil and olmesartan","slug":"azilsartan-medoxomil-and-olmesartan","indication":"Hypertension (investigational combination therapy)","status":"phase_3"},{"name":"Candesartan cilexetil / hydrochlorothiazide","genericName":"Candesartan cilexetil / hydrochlorothiazide","slug":"candesartan-cilexetil-hydrochlorothiazide","indication":"Hypertension","status":"marketed"},{"name":"Candesartan cilexetil and hydrochlorothiazide","genericName":"Candesartan cilexetil and hydrochlorothiazide","slug":"candesartan-cilexetil-and-hydrochlorothiazide","indication":"Hypertension","status":"marketed"},{"name":"Freeze-dried Human Protein C Concentrate","genericName":"Freeze-dried Human Protein C Concentrate","slug":"freeze-dried-human-protein-c-concentrate","indication":"Prevention of deep vein thrombosis and pulmonary embolism in patients with hereditary protein C deficiency","status":"phase_2"},{"name":"Hydrochlorothiazide (HCT)","genericName":"Hydrochlorothiazide (HCT)","slug":"hydrochlorothiazide-hct","indication":"Hypertension","status":"marketed"},{"name":"Lipid-lowering therapy","genericName":"Lipid-lowering therapy","slug":"lipid-lowering-therapy","indication":"Hyperlipidemia / dyslipidemia","status":"phase_3"},{"name":"SOC 4F-PCC","genericName":"SOC 4F-PCC","slug":"soc-4f-pcc","indication":"Acute coronary syndrome (Phase 3)","status":"phase_3"},{"name":"TAK-536CCB","genericName":"TAK-536CCB","slug":"tak-536ccb","indication":"Hypertension","status":"phase_3"},{"name":"TAK-816","genericName":"TAK-816","slug":"tak-816","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"Omnaris","genericName":"Alvesco","slug":"alvesco","indication":"Allergic rhinitis","status":"marketed"},{"name":"Another Available A1PI","genericName":"Another Available A1PI","slug":"another-available-a1pi","indication":"Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"dermatology","drugs":[{"name":"Lansoprazole and naproxen and aspirin","genericName":"Lansoprazole and naproxen and aspirin","slug":"lansoprazole-and-naproxen-and-aspirin","indication":"Reduction of NSAID-induced gastric ulcers in patients requiring chronic NSAID therapy for pain and inflammation","status":"phase_3"},{"name":"Magnesium Esomeprazole","genericName":"Magnesium Esomeprazole","slug":"magnesium-esomeprazole","indication":"Gastroesophageal reflux disease (GERD)","status":"marketed"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"ophthalmology","drugs":[{"name":"Elaprase","genericName":"IDURSULFASE","slug":"idursulfase","indication":"Mucopolysaccharidosis, MPS-II","status":"marketed"}]}],"pipeline":[{"name":"Entyvio","genericName":"vedolizumab","slug":"vedolizumab","phase":"marketed","mechanism":"Vedolizumab is a humanized monoclonal antibody that binds α4β7 integrin and blocks its interaction with MAdCAM-1, preventing memory T-lymphocyte migration into inflamed gastrointestinal tissue.","indications":["Chronic antibioticrefractory ileal pouchitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Vyvanse","genericName":"LISDEXAMFETAMINE","slug":"lisdexamfetamine","phase":"marketed","mechanism":"Vyvanse works by blocking the dopamine transporter, allowing more dopamine to be available in the brain.","indications":["Attention Deficit Hyperactivity Disorder (ADHD)","Moderate to severe binge eating disorder (BED)"],"catalyst":""},{"name":"Trintellix","genericName":"vortioxetine","slug":"vortioxetine","phase":"marketed","mechanism":"Vortioxetine enhances serotonergic activity through serotonin reuptake inhibition with additional 5-HT3 antagonism and 5-HT1A agonism.","indications":["Major Depressive Disorder (MDD)"],"catalyst":""},{"name":"Ninlaro","genericName":"IXAZOMIB","slug":"ixazomib","phase":"marketed","mechanism":"Ninlaro blocks the action of proteasomes, which are cellular complexes that break down and recycle proteins.","indications":["Multiple myeloma"],"catalyst":""},{"name":"Dexilant","genericName":"DEXLANSOPRAZOLE","slug":"dexlansoprazole","phase":"marketed","mechanism":"Dexlansoprazole inhibits gastric acid secretion by blocking the (H+, K+)-ATPase enzyme, known as the proton pump, in gastric parietal cells.","indications":["Erosive esophagitis","Gastroesophageal reflux disease","Maintenance of Healing Erosive Esophagitis","Peptic ulcer"],"catalyst":""},{"name":"Livtencity","genericName":"MARIBAVIR","slug":"maribavir","phase":"marketed","mechanism":"Livtencity works by inhibiting the pUL97 kinase enzyme, which is essential for the replication of cytomegalovirus.","indications":["Post-transplant cytomegalovirus infection"],"catalyst":""},{"name":"Versed","genericName":"Midazolam Hydrochloride","slug":"midazolam-hydrochloride","phase":"marketed","mechanism":"GABA A receptor alpha-5/beta-2/gamma-2","indications":["Anxiety","Conscious sedation","Feeling agitated","General anesthesia","Induce Anterograde Amnesia"],"catalyst":""},{"name":"Alunbrig","genericName":"brigatinib","slug":"brigatinib","phase":"marketed","mechanism":"Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells.","indications":["Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Amoxicillin hydrate","genericName":"Amoxicillin hydrate","slug":"amoxicillin-hydrate","phase":"phase_2","mechanism":"Amoxicillin hydrate is a beta-lactam antibiotic that inhibits cell wall synthesis in bacteria.","indications":["Uncomplicated urinary tract infections","Acute bacterial otitis media","Pharyngitis and tonsillitis caused by Streptococcus pyogenes"],"catalyst":""},{"name":"Concomitant Antibiotic Therapy","genericName":"Concomitant Antibiotic Therapy","slug":"concomitant-antibiotic-therapy","phase":"phase_3","mechanism":"Concomitant antibiotic therapy works by simultaneously administering multiple antibiotics to target bacteria through different mechanisms, reducing resistance and improving treatment efficacy.","indications":["Serious bacterial infections (specific indication dependent on Phase 3 trial design)"],"catalyst":""},{"name":"Exkivity","genericName":"MOBOCERTINIB","slug":"mobocertinib","phase":"marketed","mechanism":"Receptor tyrosine-protein kinase erbB-4","indications":["Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations"],"catalyst":""},{"name":"Firazyr","genericName":"ICATIBANT","slug":"icatibant","phase":"marketed","mechanism":"Firazyr works by blocking the action of bradykinin, a protein that causes blood vessels to swell and leads to symptoms of HAE.","indications":["Hereditary angioneurotic edema"],"catalyst":""},{"name":"Gattex Kit","genericName":"TEDUGLUTIDE","slug":"teduglutide","phase":"marketed","mechanism":"Gattex Kit works by binding to and activating the glucagon-like peptide 2 receptor, promoting intestinal growth and absorption.","indications":["Short bowel syndrome"],"catalyst":""},{"name":"IGSC 20% infusion","genericName":"IGSC 20% infusion","slug":"igsc-20-infusion","phase":"phase_3","mechanism":"IGSC 20% is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency","Autoimmune and inflammatory conditions (e.g., ITP, CIDP, myasthenia gravis)"],"catalyst":""},{"name":"Mepact","genericName":"MIFAMURTIDE","slug":"mifamurtide","phase":"marketed","mechanism":"Nucleotide-binding oligomerization domain-containing protein 2","indications":["Osteosarcoma of bone"],"catalyst":""},{"name":"Omnaris","genericName":"Alvesco","slug":"alvesco","phase":"marketed","mechanism":"Omnaris works by activating the glucocorticoid receptor to reduce inflammation in the airways.","indications":["Allergic rhinitis","Asthma","Asthma management","Seasonal allergic rhinitis"],"catalyst":""},{"name":"RYMPHYSIA","genericName":"RYMPHYSIA","slug":"rymphysia","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ramelteon and zolpidem","genericName":"Ramelteon and zolpidem","slug":"ramelteon-and-zolpidem","phase":"marketed","mechanism":"This is a fixed-dose combination of ramelteon (a melatonin receptor agonist) and zolpidem (a non-benzodiazepine hypnotic) that promotes sleep through dual mechanisms targeting different sleep-wake pathways.","indications":["Insomnia characterized by difficulty with sleep onset and/or sleep maintenance"],"catalyst":""},{"name":"TAK-003","genericName":"TAK-003","slug":"tak-003","phase":"phase_3","mechanism":"TAK-003 is a live attenuated tetravalent dengue vaccine that stimulates immune responses against all four dengue virus serotypes.","indications":["Prevention of dengue fever caused by dengue virus serotypes 1, 2, 3, and 4 in endemic populations"],"catalyst":""},{"name":"TAK-330","genericName":"TAK-330","slug":"tak-330","phase":"phase_3","mechanism":"TAK-330 is an investigational drug with a mechanism that is not fully disclosed publicly.","indications":[],"catalyst":""},{"name":"TAK-667","genericName":"TAK-667","slug":"tak-667","phase":"phase_3","mechanism":"TAK-667 is a CD47 antibody that works by blocking the interaction between CD47 and SIRPα on macrophages, thereby promoting phagocytosis of tumor cells.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"TAK-771","genericName":"TAK-771","slug":"tak-771","phase":"phase_3","mechanism":"TAK-771 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF/FGFR signaling in hepatocellular carcinoma.","indications":["Hepatocellular carcinoma (HCC), FGFR4-driven"],"catalyst":""},{"name":"TAK-861","genericName":"TAK-861","slug":"tak-861","phase":"phase_3","mechanism":"TAK-861 is a selective, reversible inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"TAK-881","genericName":"TAK-881","slug":"tak-881","phase":"phase_3","mechanism":"TAK-881 is a selective, potent, and orally bioavailable inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes","Chronic kidney disease"],"catalyst":""},{"name":"TDV","genericName":"TDV","slug":"tdv","phase":"phase_3","mechanism":"TDV is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"YF-17D","genericName":"YF-17D","slug":"yf-17d","phase":"phase_3","mechanism":"YF-17D is a live attenuated vaccine.","indications":["Prevention of yellow fever"],"catalyst":""},{"name":"AD-4833 15 mg","genericName":"AD-4833 15 mg","slug":"ad-4833-15-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AO-128","genericName":"AO-128","slug":"ao-128","phase":"marketed","mechanism":"AO-128 is a selective inhibitor of aldose reductase, an enzyme in the polyol pathway that converts glucose to sorbitol.","indications":["Diabetic peripheral neuropathy","Diabetic complications (retinopathy, nephropathy)"],"catalyst":""},{"name":"ActHIB+ DPT-TAKEDA","genericName":"ActHIB+ DPT-TAKEDA","slug":"acthib-dpt-takeda","phase":"phase_3","mechanism":"ActHIB+ DPT-TAKEDA is a combined vaccine that provides immunization against Haemophilus influenzae type b, diphtheria, pertussis, and tetanus through active immunization.","indications":["Active immunization against Haemophilus influenzae type b, diphtheria, pertussis, and tetanus in infants and children"],"catalyst":""},{"name":"Actos","genericName":"pioglitazone","slug":"pioglitazone","phase":"marketed","mechanism":"CDGSH iron-sulfur domain-containing protein 2, Bile salt export pump, CDGSH iron-sulfur domain-containing protein 1","indications":["Diabetes mellitus type 2"],"catalyst":""},{"name":"Adcal-D3","genericName":"Adcal-D3","slug":"adcal-d3","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adynovate","genericName":"Adynovate","slug":"adynovate","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Agrylin","genericName":"ANAGRELIDE","slug":"anagrelide","phase":"marketed","mechanism":"Agrylin works by inhibiting an enzyme that regulates platelet production, leading to a decrease in platelet count.","indications":["Essential thrombocythemia","Thrombocytosis in Myeloproliferative Disease"],"catalyst":""},{"name":"Alogliptin and glimepiride","genericName":"Alogliptin and glimepiride","slug":"alogliptin-and-glimepiride","phase":"phase_2","mechanism":"Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and glimepiride is a sulfonylurea that stimulates insulin release.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Alogliptin and glyburide","genericName":"Alogliptin and glyburide","slug":"alogliptin-and-glyburide","phase":"phase_3","mechanism":"Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while glyburide stimulates pancreatic beta cells to release insulin.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Alogliptin and insulin","genericName":"Alogliptin and insulin","slug":"alogliptin-and-insulin","phase":"phase_3","mechanism":"Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glucose control, while insulin provides exogenous glucose-lowering activity.","indications":["Type 2 diabetes mellitus in patients inadequately controlled on insulin alone"],"catalyst":""},{"name":"Alogliptin and metformin","genericName":"Alogliptin and metformin","slug":"alogliptin-and-metformin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alogliptin and pioglitazone","genericName":"Alogliptin and pioglitazone","slug":"alogliptin-and-pioglitazone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alogliptin and voglibose","genericName":"Alogliptin and voglibose","slug":"alogliptin-and-voglibose","phase":"phase_2","mechanism":"Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while voglibose is an alpha-glucosidase inhibitor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Another Available A1PI","genericName":"Another Available A1PI","slug":"another-available-a1pi","phase":"marketed","mechanism":"This drug replaces deficient alpha-1 protease inhibitor (A1PI) protein to prevent progressive lung damage in patients with alpha-1 antitrypsin deficiency.","indications":["Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease"],"catalyst":""},{"name":"Anti-TNF Therapy","genericName":"Anti-TNF Therapy","slug":"anti-tnf-therapy","phase":"marketed","mechanism":"Anti-TNF therapy blocks tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.","indications":["Rheumatoid arthritis","Inflammatory bowel disease (Crohn's disease and ulcerative colitis)","Psoriasis","Psoriatic arthritis","Ankylosing spondylitis"],"catalyst":""},{"name":"Any FDA Approved ALK Inhibitors","genericName":"Any FDA Approved ALK Inhibitors","slug":"any-fda-approved-alk-inhibitors","phase":"phase_2","mechanism":"ALK tyrosine kinase inhibitor","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"Azilsartan Medoxomil and amlodipine","genericName":"Azilsartan Medoxomil and amlodipine","slug":"azilsartan-medoxomil-and-amlodipine","phase":"phase_3","mechanism":"Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while amlodipine blocks calcium channels to relax blood vessels and reduce cardiac workload.","indications":["Hypertension"],"catalyst":""},{"name":"Azilsartan medoxomil - chlorthalidone","genericName":"Azilsartan medoxomil - chlorthalidone","slug":"azilsartan-medoxomil-chlorthalidone","phase":"phase_3","mechanism":"Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption.","indications":["Hypertension"],"catalyst":""},{"name":"Azilsartan medoxomil and chlorthalidone","genericName":"Azilsartan medoxomil and chlorthalidone","slug":"azilsartan-medoxomil-and-chlorthalidone","phase":"phase_3","mechanism":"Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption.","indications":["Hypertension"],"catalyst":""},{"name":"Azilsartan medoxomil and hydrochlorothiazide","genericName":"Azilsartan medoxomil and hydrochlorothiazide","slug":"azilsartan-medoxomil-and-hydrochlorothiazide","phase":"phase_3","mechanism":"Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.","indications":["Hypertension (high blood pressure)"],"catalyst":""},{"name":"Azilsartan medoxomil and olmesartan","genericName":"Azilsartan medoxomil and olmesartan","slug":"azilsartan-medoxomil-and-olmesartan","phase":"phase_3","mechanism":"This combination of two angiotensin II receptor blockers (ARBs) blocks the angiotensin II type 1 receptor to reduce blood pressure and provide cardiovascular protection.","indications":["Hypertension (investigational combination therapy)"],"catalyst":""},{"name":"Banthine","genericName":"methanthelinium","slug":"methanthelinium","phase":"marketed","mechanism":"Muscarinic acetylcholine receptor","indications":["Gastric ulcer","Peptic ulcer","Urinary incontinence"],"catalyst":""},{"name":"Calcichew D3","genericName":"Calcichew D3","slug":"calcichew-d3","phase":"marketed","mechanism":"Calcichew D3 provides supplemental calcium and vitamin D3 to maintain adequate serum calcium and phosphate levels and support bone health.","indications":["Calcium and vitamin D3 deficiency","Prevention and treatment of osteoporosis","Hypocalcemia"],"catalyst":""},{"name":"Candesartan and Hydrochlorothiazide","genericName":"Candesartan and Hydrochlorothiazide","slug":"candesartan-and-hydrochlorothiazide","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Candesartan cilexetil / hydrochlorothiazide","genericName":"Candesartan cilexetil / hydrochlorothiazide","slug":"candesartan-cilexetil-hydrochlorothiazide","phase":"marketed","mechanism":"Candesartan cilexetil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.","indications":["Hypertension","Reduction of cardiovascular risk in hypertensive patients"],"catalyst":""},{"name":"Candesartan cilexetil and hydrochlorothiazide","genericName":"Candesartan cilexetil and hydrochlorothiazide","slug":"candesartan-cilexetil-and-hydrochlorothiazide","phase":"marketed","mechanism":"Small molecule","indications":["Hypertension"],"catalyst":""},{"name":"Celecoxib and aspirin","genericName":"Celecoxib and aspirin","slug":"celecoxib-and-aspirin","phase":"phase_3","mechanism":"This combination uses celecoxib (a selective COX-2 inhibitor) and aspirin (a non-selective COX inhibitor) together to reduce inflammation and pain through complementary inhibition of cyclooxygenase enzymes.","indications":["Cardiovascular event prevention in patients with chronic pain or arthritis requiring NSAID therapy"],"catalyst":""},{"name":"Chemotherapy Agents","genericName":"Chemotherapy Agents","slug":"chemotherapy-agents","phase":"phase_2","mechanism":"Topoisomerase inhibitor","indications":["Breast cancer","Lung cancer","Colorectal cancer"],"catalyst":""},{"name":"Coumarin/troxerutin","genericName":"Coumarin/troxerutin","slug":"coumarin-troxerutin","phase":"marketed","mechanism":"Coumarin/troxerutin is a bioflavonoid combination that strengthens blood vessel walls and reduces capillary fragility through antioxidant and venoprotective effects.","indications":["Chronic venous insufficiency","Lymphedema","Hemorrhoids","Varicose veins"],"catalyst":""},{"name":"Dexlansoprazole MR","genericName":"Dexlansoprazole MR","slug":"dexlansoprazole-mr","phase":"phase_3","mechanism":"Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in parietal cells.","indications":["Gastroesophageal reflux disease (GERD)","Healing of erosive esophagitis","Maintenance of healed erosive esophagitis"],"catalyst":""},{"name":"Dexlansoprazole MR QD","genericName":"Dexlansoprazole MR QD","slug":"dexlansoprazole-mr-qd","phase":"phase_3","mechanism":"Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in parietal cells.","indications":["Gastroesophageal reflux disease (GERD)","Healing of erosive esophagitis","Maintenance of healed erosive esophagitis"],"catalyst":""},{"name":"Elaprase","genericName":"IDURSULFASE","slug":"idursulfase","phase":"marketed","mechanism":"Elaprase works by replacing the deficient enzyme iduronate-2-sulfatase in the body.","indications":["Mucopolysaccharidosis, MPS-II"],"catalyst":""},{"name":"Esomeprazole Capsule","genericName":"Esomeprazole Capsule","slug":"esomeprazole-capsule","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fazirsiran Injection","genericName":"Fazirsiran Injection","slug":"fazirsiran-injection","phase":"phase_3","mechanism":"Fazirsiran is an RNA interference (RNAi) therapeutic that silences the ALAS2 gene to reduce heme synthesis and iron accumulation in patients with iron overload disorders.","indications":["Transfusion-dependent beta-thalassemia","Iron overload disorders"],"catalyst":""},{"name":"Febuxostat IR","genericName":"Febuxostat IR","slug":"febuxostat-ir","phase":"phase_3","mechanism":"Febuxostat is a selective xanthine oxidase inhibitor that reduces uric acid production by blocking the enzyme responsible for converting hypoxanthine and xanthine to uric acid.","indications":["Chronic management of hyperuricemia in patients with gout","Prevention of gout flares"],"catalyst":""},{"name":"Freeze-dried Human Protein C Concentrate","genericName":"Freeze-dried Human Protein C Concentrate","slug":"freeze-dried-human-protein-c-concentrate","phase":"phase_2","mechanism":"Freeze-dried Human Protein C Concentrate works by replacing a clotting factor in the blood to prevent excessive clotting.","indications":["Prevention of deep vein thrombosis and pulmonary embolism in patients with hereditary protein C deficiency"],"catalyst":""},{"name":"Furacin","genericName":"NITROFURAZONE","slug":"nitrofurazone","phase":"marketed","mechanism":"Sterile alpha and TIR motif-containing protein 1","indications":["Enterobacter Cystitis","Enterococcus Urinary Tract Infection","Escherichia coli urinary tract infection","Klebsiella cystitis","Staphylococcus Aureus Urinary Tract Infection"],"catalyst":""},{"name":"Furazol","genericName":"FURAZOLIDONE","slug":"furazolidone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glibenclamide and Metformin","genericName":"Glibenclamide and Metformin","slug":"glibenclamide-and-metformin","phase":"marketed","mechanism":"Glibenclamide stimulates insulin secretion from pancreatic beta cells, while metformin reduces hepatic glucose production and improves insulin sensitivity.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Glimepiride and Metformin","genericName":"Glimepiride and Metformin","slug":"glimepiride-and-metformin","phase":"phase_3","mechanism":"Glimepiride stimulates insulin secretion from pancreatic beta cells while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HyQvia","genericName":"HyQvia","slug":"hyqvia","phase":"marketed","mechanism":"Hyaluronic acid in subcutaneous tissue; immunoglobulin G replacement","indications":["Primary Immunodeficiency (PI)"],"catalyst":""},{"name":"Hydrochlorothiazide (HCT)","genericName":"Hydrochlorothiazide (HCT)","slug":"hydrochlorothiazide-hct","phase":"marketed","mechanism":"Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, promoting water and electrolyte excretion to reduce blood volume and blood pressure.","indications":["Hypertension","Edema associated with congestive heart failure","Edema associated with renal disease","Edema associated with hepatic cirrhosis"],"catalyst":""},{"name":"IGI, 10%","genericName":"IGI, 10%","slug":"igi-10","phase":"phase_3","mechanism":"IGI is an immunoglobulin-based therapeutic that modulates immune function through Fc receptor engagement.","indications":[],"catalyst":""},{"name":"Intramuscular injection of TAK-850","genericName":"Intramuscular injection of TAK-850","slug":"intramuscular-injection-of-tak-850","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Kalcipos-D","genericName":"Kalcipos-D","slug":"kalcipos-d","phase":"marketed","mechanism":"Kalcipos-D combines calcipotriol (a vitamin D analog) with calcium carbonate to regulate calcium and phosphate metabolism and promote bone mineralization.","indications":["Hypocalcemia and vitamin D deficiency","Secondary hyperparathyroidism","Osteoporosis prevention and treatment"],"catalyst":""},{"name":"LIVTENCITY","genericName":"LIVTENCITY","slug":"livtencity","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lansoprazole and naproxen and aspirin","genericName":"Lansoprazole and naproxen and aspirin","slug":"lansoprazole-and-naproxen-and-aspirin","phase":"phase_3","mechanism":"This combination product reduces gastric acid secretion via lansoprazole while providing anti-inflammatory and analgesic effects through naproxen and aspirin, with the proton pump inhibitor protecting against NSAID-induced gastrointestinal injury.","indications":["Reduction of NSAID-induced gastric ulcers in patients requiring chronic NSAID therapy for pain and inflammation"],"catalyst":""},{"name":"Lansoprazole microgranules suspension","genericName":"Lansoprazole microgranules suspension","slug":"lansoprazole-microgranules-suspension","phase":"phase_3","mechanism":"Lansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Acid-related disorders in patients with difficulty swallowing"],"catalyst":""},{"name":"Lapaquistat acetate and atorvastatin","genericName":"Lapaquistat acetate and atorvastatin","slug":"lapaquistat-acetate-and-atorvastatin","phase":"phase_3","mechanism":"Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while atorvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis.","indications":["Hypercholesterolemia / dyslipidemia (in combination therapy)"],"catalyst":""},{"name":"Lapaquistat acetate and ezetimibe","genericName":"Lapaquistat acetate and ezetimibe","slug":"lapaquistat-acetate-and-ezetimibe","phase":"phase_3","mechanism":"Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while ezetimibe blocks NPC1L1 to further decrease cholesterol uptake, together lowering LDL cholesterol.","indications":["Hypercholesterolemia / elevated LDL cholesterol"],"catalyst":""},{"name":"Lapaquistat acetate and rosuvastatin","genericName":"Lapaquistat acetate and rosuvastatin","slug":"lapaquistat-acetate-and-rosuvastatin","phase":"phase_3","mechanism":"Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while rosuvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis.","indications":["Hypercholesterolemia / elevated LDL cholesterol"],"catalyst":""},{"name":"Lapaquistat acetate and simvastatin","genericName":"Lapaquistat acetate and simvastatin","slug":"lapaquistat-acetate-and-simvastatin","phase":"phase_3","mechanism":"Lapaquistat acetate inhibits ACAT (acyl-CoA:cholesterol acyltransferase) to reduce cholesterol absorption, while simvastatin inhibits HMG-CoA reductase to decrease cholesterol synthesis, providing dual lipid-lowering effects.","indications":["Hypercholesterolemia / dyslipidemia (LDL cholesterol reduction)"],"catalyst":""},{"name":"Leuprorelin Acetate Depot 3M","genericName":"Leuprorelin Acetate Depot 3M","slug":"leuprorelin-acetate-depot-3m","phase":"marketed","mechanism":"Leuprorelin acetate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids","Precocious puberty"],"catalyst":""},{"name":"Leuprorelin acetate","genericName":"Leuprorelin acetate","slug":"leuprorelin-acetate","phase":"phase_3","mechanism":"Leuprorelin acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.","indications":["Advanced prostate cancer","Hormone receptor-positive breast cancer","Endometriosis","Uterine fibroids","Precocious puberty"],"catalyst":""},{"name":"Levothyroxine sodium new formulation","genericName":"Levothyroxine sodium new formulation","slug":"levothyroxine-sodium-new-formulation","phase":"phase_2","mechanism":"Levothyroxine sodium acts on the thyroid hormone receptor.","indications":["Hypothyroidism"],"catalyst":""},{"name":"Lipid-lowering therapy","genericName":"Lipid-lowering therapy","slug":"lipid-lowering-therapy","phase":"phase_3","mechanism":"Lipid-lowering therapy reduces blood cholesterol and triglyceride levels through various pharmacological mechanisms to prevent cardiovascular disease.","indications":["Hyperlipidemia / dyslipidemia","Cardiovascular disease prevention","Secondary prevention post-myocardial infarction or stroke"],"catalyst":""},{"name":"Magnesium Esomeprazole","genericName":"Magnesium Esomeprazole","slug":"magnesium-esomeprazole","phase":"marketed","mechanism":"Magnesium esomeprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Prevention of NSAID-induced ulcers"],"catalyst":""},{"name":"Magnesium Pantoprazole","genericName":"Magnesium Pantoprazole","slug":"magnesium-pantoprazole","phase":"phase_3","mechanism":"Magnesium pantoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Acid-related gastrointestinal disorders"],"catalyst":""},{"name":"Metformin and insulin","genericName":"Metformin and insulin","slug":"metformin-and-insulin","phase":"marketed","mechanism":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while insulin directly replaces or supplements endogenous insulin to lower blood glucose.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"NE-58095 DR","genericName":"NE-58095 DR","slug":"ne-58095-dr","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nesina","genericName":"ALOGLIPTIN","slug":"alogliptin","phase":"marketed","mechanism":"Nesina works by blocking an enzyme that breaks down incretin hormones, allowing more insulin to be released and less glucagon.","indications":["Diabetes mellitus type 2"],"catalyst":""},{"name":"Norwalk VLP vaccine","genericName":"Norwalk VLP vaccine","slug":"norwalk-vlp-vaccine","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Olmesartan medoxomil and hydrochlorothiazide","genericName":"Olmesartan medoxomil and hydrochlorothiazide","slug":"olmesartan-medoxomil-and-hydrochlorothiazide","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Omega-3 fatty acid ethyl esters","genericName":"Omega-3 fatty acid ethyl esters","slug":"omega-3-fatty-acid-ethyl-esters","phase":"phase_2","mechanism":"Activates peroxisome proliferator-activated receptor alpha (PPAR-alpha)","indications":["Hypertriglyceridemia"],"catalyst":""},{"name":"Parathyroid Hormone (PTH)","genericName":"Parathyroid Hormone (PTH)","slug":"parathyroid-hormone-pth","phase":"marketed","mechanism":"PTH binds to PTH1 receptors on bone and kidney cells to increase serum calcium and phosphate levels, promoting bone formation and mineral homeostasis.","indications":["Osteoporosis in postmenopausal women and men at high risk of fracture","Hypoparathyroidism"],"catalyst":""},{"name":"Pioglitazone and Glimepiride","genericName":"Pioglitazone and Glimepiride","slug":"pioglitazone-and-glimepiride","phase":"marketed","mechanism":"Pioglitazone and glimepiride work together to improve glycemic control by reducing insulin resistance and stimulating insulin release.","indications":["Glycemic Control in Type 2 Diabetes","Combination Therapy for Glycemic Control"],"catalyst":""},{"name":"Pioglitazone and Metformin","genericName":"Pioglitazone and Metformin","slug":"pioglitazone-and-metformin","phase":"marketed","mechanism":"Pioglitazone improves insulin sensitivity by activating PPAR-γ, while metformin reduces hepatic glucose production and improves peripheral insulin sensitivity, together lowering blood glucose in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Pioglitazone and insulin","genericName":"Pioglitazone and insulin","slug":"pioglitazone-and-insulin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pioglitazone and metformin and insulin","genericName":"Pioglitazone and metformin and insulin","slug":"pioglitazone-and-metformin-and-insulin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo and zolpidem","genericName":"Placebo and zolpidem","slug":"placebo-and-zolpidem","phase":"marketed","mechanism":"Zolpidem is a sedative-hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.","indications":["Insomnia (sleep initiation and maintenance)"],"catalyst":""},{"name":"Placebo to alogliptin","genericName":"Placebo to alogliptin","slug":"placebo-to-alogliptin","phase":"phase_3","mechanism":"Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve blood glucose control in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Placebo to match deucravacitinib","genericName":"Placebo to match deucravacitinib","slug":"placebo-to-match-deucravacitinib","phase":"phase_3","mechanism":"Deucravacitinib is a small molecule that acts as a selective tyrosine kinase 2 (TYK2) inhibitor.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis"],"catalyst":""},{"name":"Placebo to match zasocitinib","genericName":"Placebo to match zasocitinib","slug":"placebo-to-match-zasocitinib","phase":"phase_3","mechanism":"This drug is a placebo used to match the effects of zasocitinib.","indications":[],"catalyst":""},{"name":"Rapid-acting insulin secretagogue","genericName":"Rapid-acting insulin secretagogue","slug":"rapid-acting-insulin-secretagogue","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rozerem","genericName":"RAMELTEON","slug":"ramelteon","phase":"marketed","mechanism":"Rozerem works by activating the melatonin receptor type 1A to regulate sleep-wake cycles.","indications":["Initial insomnia"],"catalyst":""},{"name":"SOC 4F-PCC","genericName":"SOC 4F-PCC","slug":"soc-4f-pcc","phase":"phase_3","mechanism":"SOC 4F-PCC is a Factor IIa protease-activated receptor 1 (PAR-1) antagonist that inhibits thrombin signaling to reduce thrombotic events.","indications":["Acute coronary syndrome (Phase 3)"],"catalyst":""},{"name":"SYR-322-MET","genericName":"SYR-322-MET","slug":"syr-322-met","phase":"phase_3","mechanism":"SYR-322-MET is a glucagon-like peptide-1 (GLP-1) receptor agonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"SYR-472","genericName":"SYR-472","slug":"syr-472","phase":"phase_3","mechanism":"SYR-472 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.","indications":["Solid tumors with FGFR gene fusions or amplifications"],"catalyst":""},{"name":"Soticlestat 300 mg","genericName":"Soticlestat 300 mg","slug":"soticlestat-300-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Surgicel® Original","genericName":"Surgicel® Original","slug":"surgicel-original","phase":"phase_3","mechanism":"Surgicel® Original is an oxidized cellulose hemostatic agent that promotes blood clotting and controls bleeding at surgical sites.","indications":["Hemostasis during surgical procedures (capillary, venous, and small arterial bleeding control)"],"catalyst":""},{"name":"TAK-019","genericName":"TAK-019","slug":"tak-019","phase":"phase_3","mechanism":"TAK-019 is a therapeutic vaccine designed to stimulate immune responses against cancer cells expressing specific tumor-associated antigens.","indications":["Melanoma (in combination with checkpoint inhibitors)","Non-small cell lung cancer (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"TAK-085","genericName":"TAK-085","slug":"tak-085","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TAK-279","genericName":"TAK-279","slug":"tak-279","phase":"phase_3","mechanism":"TAK-279 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"TAK-385","genericName":"TAK-385","slug":"tak-385","phase":"phase_3","mechanism":"TAK-385 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TAK-438","genericName":"TAK-438","slug":"tak-438","phase":"phase_3","mechanism":"TAK-438 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"TAK-536","genericName":"TAK-536","slug":"tak-536","phase":"phase_3","mechanism":"TAK-536 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TAK-536CCB","genericName":"TAK-536CCB","slug":"tak-536ccb","phase":"phase_3","mechanism":"TAK-536CCB is a dual angiotensin II receptor blocker and calcium channel blocker combination designed to lower blood pressure through multiple mechanisms.","indications":["Hypertension"],"catalyst":""},{"name":"TAK-536TCH","genericName":"TAK-536TCH","slug":"tak-536tch","phase":"phase_3","mechanism":"TAK-536TCH is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TAK-625","genericName":"TAK-625","slug":"tak-625","phase":"phase_3","mechanism":"TAK-625 is a glucagon-like peptide-1 (GLP-1) receptor agonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TAK-755","genericName":"TAK-755","slug":"tak-755","phase":"phase_3","mechanism":"TAK-755 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TAK-816","genericName":"TAK-816","slug":"tak-816","phase":"phase_3","mechanism":"TAK-816 is a selective, reversible inhibitor of the sodium-activated potassium channel Nav1.5.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"TAK-816+ DPT-TAKEDA","genericName":"TAK-816+ DPT-TAKEDA","slug":"tak-816-dpt-takeda","phase":"phase_3","mechanism":"TAK-816 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TAP-144-SR(3M)","genericName":"TAP-144-SR(3M)","slug":"tap-144-sr-3m","phase":"phase_3","mechanism":"TAP-144-SR is a sustained-release formulation of leuprolide, a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone to reduce sex hormone production.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids","Precocious puberty"],"catalyst":""},{"name":"TAP-144-SR(6M)","genericName":"TAP-144-SR(6M)","slug":"tap-144-sr-6m","phase":"phase_3","mechanism":"TAP-144-SR is a sustained-release formulation of leuprolide, a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone to reduce sex hormone production.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids","Precocious puberty"],"catalyst":""},{"name":"TVP-1012","genericName":"TVP-1012","slug":"tvp-1012","phase":"phase_3","mechanism":"TVP-1012 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1).","indications":["Multiple sclerosis"],"catalyst":""},{"name":"Tinoridine HCl","genericName":"Tinoridine HCl","slug":"tinoridine-hcl","phase":"marketed","mechanism":"Tinoridine HCl is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis and inflammation.","indications":["Rheumatoid arthritis","Osteoarthritis","Inflammatory pain conditions"],"catalyst":""},{"name":"Uloric","genericName":"FEBUXOSTAT","slug":"febuxostat","phase":"marketed","mechanism":"Uloric works by blocking the enzyme xanthine dehydrogenase/oxidase, which is involved in the production of uric acid.","indications":["Gout Prevention","Hyperuricemia"],"catalyst":""},{"name":"VONVENDI","genericName":"VONVENDI","slug":"vonvendi","phase":"marketed","mechanism":"VONVENDI is a recombinant von Willebrand factor (VWF) that replaces deficient or dysfunctional VWF to restore platelet adhesion and hemostasis.","indications":["Von Willebrand disease (on-demand treatment and routine prophylaxis of bleeding episodes)"],"catalyst":""},{"name":"Vedolizumab IV","genericName":"Vedolizumab IV","slug":"vedolizumab-iv","phase":"marketed","mechanism":"Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on gut-homing lymphocytes, preventing their migration to the gastrointestinal tract.","indications":["Moderate to severe ulcerative colitis","Moderate to severe Crohn's disease"],"catalyst":""},{"name":"Vedolizumab SC","genericName":"Vedolizumab SC","slug":"vedolizumab-sc","phase":"marketed","mechanism":"Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on gut-homing lymphocytes, preventing their migration to the gastrointestinal tract.","indications":["Ulcerative colitis (induction and maintenance of remission)","Crohn's disease (induction and maintenance of remission)"],"catalyst":""},{"name":"Venticute","genericName":"Venticute","slug":"venticute","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vortioxetine tablets","genericName":"Vortioxetine tablets","slug":"vortioxetine-tablets","phase":"phase_3","mechanism":"Vortioxetine is a serotonin modulator and stimulator that acts as a selective 5-HT3 receptor antagonist, 5-HT1A receptor agonist, 5-HT7 receptor agonist, and norepinephrine reuptake inhibitor.","indications":["Major depressive disorder"],"catalyst":""},{"name":"mannitol and sucrose","genericName":"mannitol and sucrose","slug":"mannitol-and-sucrose","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-09","type":"regulatory","headline":"Takeda Receives FDA Approval for RYMPHYSIA","summary":"Takeda announced that the FDA has approved RYMPHYSIA (palbociclib) for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.","drugName":"RYMPHYSIA","sentiment":"positive"},{"date":"2022-07-28","type":"earnings","headline":"Takeda Reports Second-Quarter 2022 Financial Results","summary":"Takeda announced its second-quarter 2022 financial results, with revenue of ¥1,444.8 billion and a net loss of ¥14.4 billion.","drugName":"","sentiment":"neutral"},{"date":"2022-06-01","type":"deal","headline":"Takeda to Acquire Shire for $62 Billion","summary":"Takeda announced that it has entered into a definitive agreement to acquire Shire for $62 billion.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBqakE1TEZOTFhHdU9IbHJMTGJwNUpYRENKdks5LUhNSGViODJ5TWJ0RTdrbnB2OVB2bFowOWJLRGljSkVvSnNGOGhRXzNGNU5H?oc=5","date":"2026-04-06","type":"pipeline","source":"Yahoo Finance","summary":"Takeda Pharmaceutical Company Limited (4502.T) Stock Price, News, Quote & History - Yahoo Finance","headline":"Takeda Pharmaceutical Company Limited (4502.T) Stock Price, News, Quote & History","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOMXBKQjVNeEcyeG11MHBkek51QjBoMHY4d3JzZWotckppck13OG5nU19mMGhvNFIzWElLcnl2OUlJN3M0eXhjdk1DaExPa251YXIza0FCd2FpblNnTXgybmR5VW84M1hlNXRMaTNZMldmYzJaZGhjY1Y2NjRLNHN5VmNCMEo3bW9GVDBLZ09qcmE2cXlvbTFDQTZxMnRpRWdpZzBydzlkRkZETl9LZVlYbTJCdHhIcGhwTWttdnBPaG54S1VJRWdCMW93?oc=5","date":"2026-03-18","type":"pipeline","source":"Stock Titan","summary":"Takeda (NYSE: TAK) Japan Pharma chief details shares, RSUs and tax awards - Stock Titan","headline":"Takeda (NYSE: TAK) Japan Pharma chief details shares, RSUs and tax awards","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPRHFQanhyLTJuSmJiZVNyQlIxQXJQMHFkaHEyUmRCZVptWTJIbzQ2ZEFlZzhJYnhRLUR4aDkxTzFmRDJCRVRRSWRCZ2RFMlVqRHFYSWUzNlM4R2R1Zko5RWFnVnp2UkRMLTVEMnhxdlVjUlJ2aDh5RjE5dnIxYW9vbUZxVTEyQQ?oc=5","date":"2026-03-08","type":"regulatory","source":"Yahoo Finance","summary":"FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment - Yahoo Finance","headline":"FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPc05hQlpzVDhyTHNtSHZkdGdLN2M0VVdyRnZ6cExDZHc0eU81aEJUMFg0YmI1cXZXS2o4YVNnbVlrWTVmUXNYRnpSWlVRRGFFWDNYdjEwVnUteU5yX3VNNjg1WjhyVWZXaV85akhhUlVSRHJpTHhpZTJpMDd3d2xOTE5iSjVFMHIzcEJMeTB6eXpOc1Z4WmhPQkI4WnFpcWN6Qi1ja0FmaDl4WTBFdTlHb1ItMl85bDlpU2phV28yenlLZFlrOFhhM2pPZl93dw?oc=5","date":"2026-02-09","type":"deal","source":"Benzinga","summary":"Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga","headline":"Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQN1gweHhvR0hnaFFSdlB1LU10aEc2UnYyTURLaXBjbVZ0SXJtSjhLc3FkZm9iMFNMazVuZWdCT2NwV0RuZ01uZ2w4aFpKZW9TZmNNNXdwMFFWWjZXSVctenVnX1lsdFIwX0xyUEZfSHpQM1AwZG80MEJJNU8xZ0NzSW1HbzhrSjdwOUlLVGUzNDNMNDlJZVBPaUxjWGRPQTdSTmN2VVBB?oc=5","date":"2026-01-30","type":"pipeline","source":"Seeking Alpha","summary":"Takeda Tests New Highs, But Struggles To Find Entyvio Successor (NYSE:TAK) - Seeking Alpha","headline":"Takeda Tests New Highs, But Struggles To Find Entyvio Successor (NYSE:TAK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPOUdaLWJ1Y3hhTnJxWlNkVGtYNnZidDkxcW1BUEdCSmJ2RF9vS2NUeEhRdGdwNlhzRGM1ZW56ZXdndlIzVFNueENMR0dRb2YwbnZaTnQtM1hEQUVEcjNvaXc0b3BhSnAzRGl0YUM2a21UNkpaa2NTVDhMZ2ZWdFZvTkp0T3N6ckdfMy13SldTMHM5elkySmV5N0Vsc0JiQzJlVEZEdndUM1JVZEhfNU9NSXR5TGNQRjV2eHBZRjV3N2h6dnM?oc=5","date":"2026-01-29","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: Takeda Pharma Q3 2026 sees mixed performance - Investing.com","headline":"Earnings call transcript: Takeda Pharma Q3 2026 sees mixed performance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNdDJHbkJwdkQtZ1g0a1dUY2NIMjg4TmZxcmhZa2lmLS1MckpnMjRhbUNyWDJGUGxIbnRyaExZRWkzenNmQldPQkVZOTJFcTdCRXBEeG5heGtGTFhwSlQybTF6MzBqdDhIaW5LSG4wWjlsM3llM1BPYVFyemtndFpIbm8wZmRETkdETkI1N3gxT2hnMG9EUjQxRjRZVzY3SHFSX1l1ZFcyQ0ctWGZBaE1ybmdB?oc=5","date":"2026-01-28","type":"earnings","source":"Benzinga","summary":"Insights into Takeda Pharmaceutical's Upcoming Earnings - Benzinga","headline":"Insights into Takeda Pharmaceutical's Upcoming Earnings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPckc3aUR3TTRPMjVnQkFKRmxNRVZTQk5XdG41T0tZZnZnaDNERENKemd4dmNpRFhBU1dycV96MTQxVzBidkYyWTlSamVmSmhBQ3FGVGRkY0p2MndhT0Q4UXMwSThfNDBLWTJyWGd2akZZRUNHZGdFUFhoS3pqRGZ5cDFvVVQ5VmE2bHlTemIxcWM5VXhHMWc?oc=5","date":"2025-12-11","type":"pipeline","source":"Seeking Alpha","summary":"Takeda: Lack Of Realistic Upside In Japanese Pharma (NYSE:TAK) - Seeking Alpha","headline":"Takeda: Lack Of Realistic Upside In Japanese Pharma (NYSE:TAK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNV3ozY1pXSFlpRXctN2VaR3BwSWtsVGZJU1J6X2FURk9ac0JCZVRDSGdBMGM3V2ZqMUhrWEdKWUFKaV9lME9vejVSQUlRemoxbjZoLWFlekhVLTl5T2lqVUVZd21oZWdyQ1Vic204WmpiWU5ZSHBDaUJzdEU4VzNudnUwbzNneWtaSDQzQm93?oc=5","date":"2025-10-21","type":"deal","source":"Yahoo Finance","summary":"Takeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla Bio - Yahoo Finance","headline":"Takeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla Bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOWi14YWd0SHE1NjRlWTdfdjZyYVBiSS1ka2s4dElqMmdtdGFhc0d4NU5DREpJYk1FTzhzTnprZ3dwaXhndUFGNW10LTNINEtnaGpBMmJFYUJlb3Y0c2xxNGdURWd3QXVEWnhHVjhWdlNlOTRnUXByOFpHQ2Q4TjV0V2dlMGVEc3lqZ2xiMno4ckg3NTRxaVh6V05QNGZ6cjVfTVhj?oc=5","date":"2025-09-24","type":"pipeline","source":"Seeking Alpha","summary":"Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually (NYSE:TAK) - Seeking Alpha","headline":"Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually (NYSE:TAK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQTVh3SU9GZE5jZTloaHFEYmNWaXF3Y21EaVQ3TVhaZVc2TkhoZlp3YzJtc05GRm12ZmpuNFVGN2t6STgwUlVfSmVRZTMzWFhsRlZaYmI4ZlNDVkx2bXBZYXJOOThxVldacFNHbklSSWR6SjNJVjFoZXgyUDRNMHlBOTB5c3dtOXF1VGV3a2FCM2l0QnpINUNKNDFZaUwwRjBYVXVIQWdkNV9RUldXNGlFZXI1XzRXU0IzZnNiZHNXdw?oc=5","date":"2025-09-16","type":"pipeline","source":"Stock Titan","summary":"99% Emissions Cut: Takeda Launches Revolutionary Wind-Powered Ocean Shipping for Medicines - Stock Titan","headline":"99% Emissions Cut: Takeda Launches Revolutionary Wind-Powered Ocean Shipping for Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOZ3NFcW16bmFTY2lNMklJd29abGZISGtYVkU0YmdrMktPTS12cnNUZzFPdXRZQkZGOUc3YlBDNWJIdEV3cndOMlJuQjk5RDJONTBFaWQ1bjJHSUpFYzV2eVpWbHBnTFdTeXZGbWowVkc2cHJWaFh2WldoUDZUNUVsQnhwQnRWNHotRDRUQUZCMlBXbFlrY2VjTGJKMGx6a0RyX204blVwd0ppd1pVUW1JWktFUm56VWhybVdDRmJmek4?oc=5","date":"2025-07-30","type":"pipeline","source":"Benzinga","summary":"Why Is Takeda Pharma Stock Falling On Wednesday? - Takeda Pharmaceutical Co (NYSE:TAK) - Benzinga","headline":"Why Is Takeda Pharma Stock Falling On Wednesday? - Takeda Pharmaceutical Co (NYSE:TAK)","sentiment":"neutral"}],"patents":[{"drugName":"Dexilant","drugSlug":"dexlansoprazole","patentNumber":"7790755","type":"Formulation","expiryDate":"2026-08-02","territory":"US","annualRevenue":300000000,"genericFilings":[]},{"drugName":"Dexilant","drugSlug":"dexlansoprazole","patentNumber":"8105626","type":"Formulation","expiryDate":"2026-09-27","territory":"US","annualRevenue":300000000,"genericFilings":[]},{"drugName":"Dexilant","drugSlug":"dexlansoprazole","patentNumber":"7790755*PED","type":"Compound","expiryDate":"2027-02-02","territory":"US","annualRevenue":300000000,"genericFilings":[]},{"drugName":"Dexilant","drugSlug":"dexlansoprazole","patentNumber":"8105626*PED","type":"Compound","expiryDate":"2027-03-27","territory":"US","annualRevenue":300000000,"genericFilings":[]},{"drugName":"Versed","drugSlug":"midazolam-hydrochloride","patentNumber":"9687495","type":"Formulation","expiryDate":"2028-01-18","territory":"US","genericFilings":[]},{"drugName":"Versed","drugSlug":"midazolam-hydrochloride","patentNumber":"9289432","type":"Formulation","expiryDate":"2028-01-18","territory":"US","genericFilings":[]},{"drugName":"Versed","drugSlug":"midazolam-hydrochloride","patentNumber":"8217033","type":"Formulation","expiryDate":"2028-01-18","territory":"US","genericFilings":[]},{"drugName":"Versed","drugSlug":"midazolam-hydrochloride","patentNumber":"8809322","type":"Formulation","expiryDate":"2028-01-18","territory":"US","genericFilings":[]},{"drugName":"Oxaliplatin","drugSlug":"oxaliplatin","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Vedolizumab","drugSlug":"vedolizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":2500000000},{"drugName":"Dexilant","drugSlug":"dexlansoprazole","patentNumber":"8173158","type":"Method of Use","expiryDate":"2030-03-17","territory":"US","annualRevenue":300000000,"genericFilings":[]},{"drugName":"Dexilant","drugSlug":"dexlansoprazole","patentNumber":"8173158*PED","type":"Compound","expiryDate":"2030-09-17","territory":"US","annualRevenue":300000000,"genericFilings":[]},{"drugName":"Dexilant","drugSlug":"dexlansoprazole","patentNumber":"9233103","type":"Method of Use","expiryDate":"2032-03-05","territory":"US","annualRevenue":300000000,"genericFilings":[]},{"drugName":"Versed","drugSlug":"midazolam-hydrochloride","patentNumber":"10966990","type":"Formulation","expiryDate":"2038-06-20","territory":"US","genericFilings":[]}],"drugCount":129,"phaseCounts":{"marketed":58,"phase_2":9,"phase_3":58,"phase_1":4},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Pfizer","Merck & Co.","Eli Lilly and Company"],"therapeuticFocus":["Oncology","Gastroenterology","Neuroscience"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":18.62,"previousClose":18.29,"fiftyTwoWeekHigh":18.9,"fiftyTwoWeekLow":12.99,"fiftyTwoWeekRange":"12.99 - 18.9","fiftyDayAverage":18.02,"twoHundredDayAverage":15.56,"beta":0.13,"enterpriseValue":4797065854976,"forwardPE":35.1,"priceToBook":0.61,"priceToSales":0.01,"enterpriseToRevenue":1.07,"enterpriseToEbitda":3.77,"pegRatio":0.41,"ebitda":1273957056512,"ebitdaMargin":28.5,"freeCashflow":536711266304,"operatingCashflow":1189061984256,"totalDebt":5421965246464,"debtToEquity":70.9,"currentRatio":1.19,"returnOnAssets":2.5,"returnOnEquity":1.5,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":3,"targetMeanPrice":20.67,"targetHighPrice":22.03,"targetLowPrice":18.77,"dividendRate":0.66,"payoutRatio":2.79,"fiveYearAvgDividendYield":4.61,"exDividendDate":1759190400,"insiderHeldPercent":0,"institutionHeldPercent":2.7,"sharesOutstanding":3159192822,"floatShares":1577969427,"sharesShort":5874776,"shortRatio":2.39,"shortPercentOfFloat":0.2,"epsTrailing":0.22,"epsForward":0.53,"revenuePerShare":1417.23,"bookValue":30.51,"officers":[{"age":59,"name":"Mr. Christophe P.  Weber","title":"President, CEO & Representative Director"},{"age":47,"name":"Mr. Milano  Furuta","title":"CFO & Director"},{"age":60,"name":"Dr. Andrew S.  Plump M.D., Ph.D.","title":"President of Research & Development and Representative Director"},{"age":null,"name":"Dr. Seigo  Izumo","title":"Chair of Management Board"},{"age":68,"name":"Mr. Haruhiko  Hirate","title":"Member of Management Board"},{"age":50,"name":"Mr. Salvatore  Alesci M.D., Ph.D.","title":"Member of Management Board and Head of R&D Global Science & Biomedical Policy"},{"age":null,"name":"Norimasa  Takeda","title":"Chief Accounting Officer & Corporate Controller"},{"age":null,"name":"Mr. Iwaaki  Taniguchi","title":"Senior Vice President of Corporate Finance & Controlling Department"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"http://www.takeda.com/investor-information/","website":"https://www.takeda.com","phone":"81 3 3278-2111"}}